A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity

BMC Cancer

Table 3 Tumor growth inhibition in A549 xenograft model

Drugs	Mean Tumor Volume	Growth inhibition (TGI%)	P value vs PBS	P value vs Bevacizumab
HB-002.1, 5 mg/kg	2.72 (2.51-2.91)	78.02	<0.0001	<0.0001
HB-002.1, 20 mg/kg	1.89 (1.66-2.16)	84.71	<0.0001	<0.0001
Bevacizumab, 5 mg/kg	4.40 (3.59-5.40)	64.46	<0.0001	NA
Bevacizumab, 20 mg/kg	4.02 (3.36-4.81)	67.55	<0.0001	NA
PBS	12.38 (9.87-15.54)	0.00	NA	NA

Sample size = 10 for each group.
Mean Tumor Volume = geometric mean with 95% confidence interval in parentheses. Geometric mean is shown because statistical analyses utilized log-transformed data that best modeled tumor volume growth.
P value was calculated as described in Methods.
P value vs Bevacizumab is compared to same dose of HB-002.1.
NA = not applicable.

ISSN: 1471-2407